{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:02:33Z","timestamp":1787061753604,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The objective of this phase 1 study was to evaluate the pharmacokinetics, safety, and tolerability of baricitinib after single and multiple doses in healthy Chinese adults. Eligible subjects received a once\u2010daily dose of baricitinib 2, 4, or 10 mg or placebo on day 1 (single dose) and days 4 through 10 for 7 consecutive days (multiple doses). Plasma pharmacokinetic samples were collected up to 48 hours after dosing on days 1 and 10, with predose samples collected before dosing on day 1 and days 4 through 10. Safety and tolerability were also assessed. Baricitinib was rapidly absorbed, reaching peak plasma concentrations within 0.5 to 1 hour (median). Plasma concentrations declined rapidly following the attainment of peak concentrations, with a mean terminal half\u2010life of 5.7 to 7.3 hours. Steady\u2010state plasma concentrations of baricitinib were achieved after the second day of once\u2010daily dosing, with minimal accumulation of baricitinib in plasma (up to 10% increase in area under the plasma concentration\u2013time curve). Single\u2010 and multiple\u2010dose mean values for area under the plasma concentration\u2013time curve from time zero to infinity and maximum plasma concentration appeared to increase in an approximately dose\u2010proportional manner across the dose range. Single and multiple oral doses of once\u2010daily baricitinib up to 10 mg were well tolerated by healthy Chinese subjects.<\/jats:p>","DOI":"10.1002\/cpdd.868","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T23:51:42Z","timestamp":1600386702000},"page":"952-960","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetics, Safety, and Tolerability of Single\u2010 and Multiple\u2010Dose Once\u2010Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo\u2010Controlled Study"],"prefix":"10.1002","volume":"9","author":[{"given":"Xia","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yan","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[{"name":"Medical Department Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Department Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Department Lilly Suzhou Pharmaceutical Co. Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Min","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0190-5"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"issue":"4","key":"e_1_2_10_5_1","first-page":"694","article-title":"The effect of JAK1\/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib","volume":"37","author":"Choy EHS","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918604"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key225"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0908-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010037"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206478"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.354"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1744435"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.936"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S192440"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12486"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12251"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003256065"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7551.1163"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-015-0101-3"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:55:04Z","timestamp":1693223704000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/cpdd.868"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.868","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"2019-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}